Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B	MYTX-011 Sensitive: B - Late Trials MYTX-011 Sensitive : B
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2	gumarontinib Sensitive: C2 – Inclusion Criteria gumarontinib Sensitive : C2
MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	MET overexpression	Lung Non-Squamous Non-Small Cell Cancer	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2	telisotuzumab vedotin-tllv Sensitive: C2 – Inclusion Criteria telisotuzumab vedotin-tllv Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2	tepotinib Sensitive: C2 – Inclusion Criteria tepotinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2	osimertinib + savolitinib Sensitive: C2 – Inclusion Criteria osimertinib + savolitinib Sensitive : C2
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3	erlotinib + ARQ 197 Sensitive: C3 – Early Trials erlotinib + ARQ 197 Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3	ARQ 197 Sensitive: C3 – Early Trials ARQ 197 Sensitive : C3
MET overexpression	Melanoma	MET overexpression	Melanoma	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3	vemurafenib Resistant: C3 – Early Trials vemurafenib Resistant : C3
MET overexpression	Colorectal Cancer	MET overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
MET overexpression	Glioblastoma	MET overexpression	Glioblastoma	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3	bevacizumab Resistant: C3 – Early Trials bevacizumab Resistant : C3
MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3	tepotinib Sensitive: C3 – Early Trials tepotinib Sensitive : C3
MET overexpression	Gastric Cancer	MET overexpression	Gastric Cancer	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3	crizotinib Sensitive: C3 – Early Trials crizotinib Sensitive : C3